ACAD News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

AC

Mkt Cap

$3.30B

Volume

1.25M

Next Earnings

November 4th

Loading chart

AC

ACADAcadia Pharmaceuticals Inc.

ACAD

Pay with—

Available Balance0.00

AC

Mkt Cap

$3.29B

Volume

1.25M

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects?Acadia Pharmaceuticals generated $576 million in first-half 2026 revenues, up 13% year-over-year, and raised its full-year 2026 guidance to $1.24-$1.30 billion. Nuplazid sales grew 7% to $350.1 million with patent protection until February 2038, while Daybue sales jumped 25% to $226 million, driven by the new STIX formulation and EU approval for Rett syndrome treatment. However, ACAD shares have underperformed the industry by 27.3% year-to-date and face increasing competition from rivals like Axsome and Neurogene.Zacks Investment Research · Oct 13, 2026

4 CNS Drug Stocks Worth Watching This World Mental Health DayFour central nervous system (CNS) pharmaceutical companies—Axsome Therapeutics, Neurocrine Biosciences, Alkermes, and Acadia Pharmaceuticals—are highlighted as relevant investment opportunities ahead of World Mental Health Day. All four companies carry a Zacks Rank #3 (Hold) rating and have strong CNS portfolios with meaningful revenue growth in H1 2026, supported by expanding pipelines addressing psychiatric and neurological disorders.Zacks Investment Research · Oct 9, 2026

Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041Acadia Pharmaceuticals received a Notice of Allowance from the USPTO that extends patent protection for trofinetide (Daybue) to March 2041, adding nearly five years to existing coverage. Daybue sales grew 25% to $226 million in H1 2026, and the drug received EU approval in August 2026, becoming the first and only approved treatment for Rett syndrome in Europe.Zacks Investment Research · Sep 29, 2026

Why Acadia Pharmaceuticals Stock Is Soaring TodayAcadia Pharmaceuticals shares surged 12.2% after the European Medicines Agency's Committee recommended approval of Daybue for Rett syndrome treatment in the EU. The company, which focuses on rare neurological and psychiatric disorders, is profitable with two approved drugs generating significant revenue. While the European market for Rett syndrome may be modest, Acadia faces minimal competition in its niche.The Motley Fool · Jun 26, 2026

Acadia Stock Up 59% in a Year — Is a $51 Million New Stake a Bet on a Bigger Rebound?Connecticut-based fund Braidwell established a new $50.8 million stake in Acadia Pharmaceuticals, representing 2.1% of its reportable U.S. equity assets, as the company shows strong quarterly performance and potential for growth in neurological disorder treatments.The Motley Fool · Dec 4, 2025

Questex’s Fierce Pharma Announces the 2025 Fierce Pharma Marketing Awards WinnersQuestex's Fierce Pharma Marketing Awards celebrated innovative pharmaceutical marketing campaigns across 18 categories, highlighting creative approaches to addressing global health challenges.GlobeNewswire Inc. · Sep 11, 2025

Parkinson’s Disease Therapeutic Domain Projected to See Transformational Growth Across the 7MM During the Study Period (2020–2034) | DelveInsightThe Parkinson's disease market is expected to grow significantly due to the introduction of emerging therapies, advancements in treatment options, and a rising prevalence of the condition.GlobeNewswire Inc. · Apr 22, 2025

Neuroregeneration Therapy Market to Surpass USD 64.8 Billion by 2034, Driven by Advancements in Regenerative Medicine and Rising Neurological Disorders | Transparency Market ResearchThe global neuroregeneration therapy market is expected to grow significantly, driven by advancements in regenerative medicine and the rising prevalence of neurological disorders. Key players are investing heavily in R&D, leading to innovative therapies and clinical trials that are accelerating market expansion.GlobeNewswire Inc. · Feb 11, 2025

This Vertex Pharmaceuticals Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For ThursdayTop Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page. BMO Capital analyst Keith Tapper initiated coverage on ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with an Outperform rating and announced a price target of $31. ACADIA Pharmaceuticals shares fell 0.6% to close at $15.50 on Wednesday. See how other analysts view this stock. Mizuho analyst Wei Fang initiated coverage on Grab Holdings Limited (NASDAQ:GRAB) with an Outperform rating and announced a price target of $5. Grab shares fell 0.3% to ...Full story available on Benzinga.comBenzinga · Jun 27, 2024

Alnylam (ALNY) Soars 5.3%: Is Further Upside Left in the Stock?Alnylam (ALNY) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions could translate into further price increase in the near term.Zacks Investment Research · Jun 24, 2024

to start trading

AC

ACADAcadia Pharmaceuticals Inc.

ACAD

Pay with—

Available Balance0.00

Your PositionYou don't own any ACAD yet.

Related Tickers

Earnings